Thermo Fisher Scientific TMO
Thermo Fisher Scientific is a leading global provider of instruments, reagents, consumables, and services for research, diagnostics, and life sciences laboratories. Thermo Fisher combines solid growth (revenue +10.5%) with operating margins of 18.75%, but its demanding valuation (P/E 36.37) and leverage of 3.28x EBITDA limit the margin of error; momentum is strong (97th percentile in 52 weeks).
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
Thermo Fisher Scientific is a leading global provider of instruments, reagents, consumables, and services for research, diagnostics, and life sciences laboratories. Thermo Fisher combines solid growth (revenue +10.5%) with operating margins of 18.75%, but its demanding valuation (P/E 36.37) and leverage of 3.28x EBITDA limit the margin of error; momentum is strong (97th percentile in 52 weeks).
Score by category
| Category | Score |
|---|---|
| Financial health | 5.6 |
| Quality / Moat | 5.5 |
| Valuation | 3.4 |
| Growth | 6.7 |
| Dividend | 2.9 |
| Momentum | 7.7 |
| Risk & Context | 6.6 |
OVERALL SCORE: 5.4/10
Context and risks
Moderate regulatory exposure in the US due to scrutiny over pricing of medical devices and diagnostics. No material exposure to rates, oil, or geopolitics affecting its lab instruments and consumables business.
News considered in the analysis
- Pfizer vs. Thermo Fisher: Which Healthcare Turnaround has More Upside? — Comparativa de análisis sin información nueva sobre Thermo Fisher.
- What Needs To Be True To Buy Twist Bioscience Stock Now? — Análisis sobre otra empresa, sin impacto directo en Thermo Fisher.
- Here's How Much a $1000 Investment in Thermo Fisher Scientific Made 10 Years Ago Would Be Worth Today — Listículo retrospectivo sobre rentabilidad pasada, sin información nueva.
- Dodge and Cox’s Bullish Stance on Thermo Fisher Scientific (TMO) — Respaldo de un gestor de fondos de primer nivel, señal moderadamente positiva de confianza institucional.
- Biodesix Advances MRD Monitoring Programs With Bio-Rad and Thermo Fisher — Colaboración en un área de alto crecimiento (monitorización de enfermedad residual mínima), refuerza la posición en diagnóstico oncológico.
Verdict: Hold; business quality and growth justify the premium, but valuation and debt suggest waiting for a better entry point.
Main risk: Leverage of 3.28x Net Debt/EBITDA in a still-elevated rate environment, which could compress free cash flow generation (53% conversion) if growth decelerates.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →